Product Description
Mechanisms of Action: CB1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Peru | Portugal | Slovenia | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Healthy Volunteers|Obesity|Insulin Resistance|Inflammation|Overweight|Other|Atherosclerosis|Diabetes, Gestational|Dyslipidemia|Cocaine-Related Disorders|Obesity, Abdominal|Alcoholism
Phase 3: Type 2 Diabetes|Obesity|Glucose Intolerance|Prediabetic State|Other|Dyslipidemia|Tobacco Use Disorder|Smoking Cessation|Overweight|Atherosclerosis|Weight Loss|Myocardial Ischemia|Albuminuria|Coronary Artery Disease|Carotid Stenosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Obesity, Abdominal|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Stroke|Myocardial Infarction|Metabolic Syndrome X|Arteriosclerosis|Schizophrenia|Weight Gain|Prader-Willi Syndrome|Spinal Cord Injuries
Phase 2: Alcoholic Intoxication|Marijuana Abuse|Obesity|Spinal Cord Injuries|Polycystic Ovary Syndrome|Tobacco Use Disorder|Psychotic Disorders|Affective Disorders, Psychotic|Schizophrenia|Hypertension
Phase 1: Marijuana Abuse
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618000263291p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Dementia |
2018-11-26 |
|||
2007-002492-14 |
MODERATO | N/A |
Completed |
Type 2 Diabetes|Dyslipidemia |
2009-02-27 |
2022-03-12 |
Treatments |
|
NCT01041170 |
06-DA-N410 | P1 |
Completed |
Marijuana Abuse |
2010-01-11 |
2019-03-19 |
Treatments |
|
NCT05622994 |
RIMOFATSCI-2 | P2 |
Unknown status |
Spinal Cord Injuries |
2023-11-01 |
2024-11-02 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05398913 |
RIMOFATSCI-1 | P2 |
Completed |
Spinal Cord Injuries |
2022-06-07 |
2022-11-16 |
||
NCT00656487 |
SCCAN | P2 |
Completed |
Marijuana Abuse |
2010-12-28 |
2019-03-18 |
Treatments |
|
NCT00547118 |
HP-00041206 | P2 |
Terminated |
Tobacco Use Disorder|Affective Disorders, Psychotic|Psychotic Disorders|Obesity|Hypertension|Schizophrenia |
2009-03-01 |
2019-11-05 |
Primary Endpoints|Treatments |
|
2022-001522-30 |
2022-001522-30 | P3 |
Active, not recruiting |
Spinal Cord Injuries |
2024-09-29 |
|||
2008-002500-26 |
2008-002500-26 | P3 |
Terminated |
Type 2 Diabetes |
2010-09-08 |
2022-03-12 |
Treatments |
|
2008-001015-38 |
2008-001015-38 | P3 |
Active, not recruiting |
Schizophrenia |
2010-07-23 |
2022-03-12 |
Treatments |
|
2007-002077-31 |
EFFECTS | P3 |
Terminated |
Type 2 Diabetes|Albuminuria |
2009-07-22 |
2022-03-12 |
Treatments |
|
2005-002942-20 |
CRESCENDO | P3 |
Withdrawn |
Stroke|Obesity, Abdominal |
2009-04-29 |
2022-03-12 |
Treatments |
|
NCT00263042 |
CRESCENDO | P3 |
Terminated |
Myocardial Infarction|Obesity, Abdominal|Stroke |
2009-04-01 |
2019-03-21 |
||
NCT00228176 |
AUDITOR | P3 |
Terminated |
Obesity|Arteriosclerosis|Atherosclerosis|Carotid Stenosis|Metabolic Syndrome X |
2009-04-01 |
2019-03-21 |
Treatments |
|
2006-005385-39 |
ALLEGRO | P3 |
Completed |
Overweight |
2009-03-04 |
2022-03-12 |
Treatments |
|
NCT00325650 |
RAPSODI | P3 |
Terminated |
Glucose Intolerance|Prediabetic State |
2009-03-01 |
2019-03-21 |
Treatments |
|
2007-004833-40 |
TOCCATA | P3 |
Terminated |
Type 2 Diabetes |
2009-02-18 |
2025-06-28 |
Treatments |
|
2007-003012-61 |
STRONG | P3 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2009-02-27 |
2022-03-12 |
Treatments |
|
NCT00546325 |
REASSURE | P3 |
Completed |
Type 2 Diabetes|Overweight |
2009-02-01 |
2019-03-21 |
||
NCT00576667 |
EFC10143 | P3 |
Terminated |
Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease |
2009-02-01 |
2019-03-22 |
Treatments |
|
2011-003104-20 |
Effec Acomplia gastric sensitivity | P4 |
Completed |
Healthy Volunteers |
2021-03-03 |
2022-03-13 |
Treatments |
|
2008-005538-59 |
2008-005538-59 | P4 |
Active, not recruiting |
Cocaine-Related Disorders|Alcoholism |
2011-02-18 |
2022-03-12 |
Treatments |
|
2007-000907-13 |
RIGD | P4 |
Completed |
Obesity, Abdominal|Diabetes, Gestational |
2010-03-16 |
2022-03-12 |
Treatments |
|
NCT00584389 |
EC/2006/117/PGMS | P4 |
Terminated |
Obesity |
2009-04-01 |
2019-03-22 |
Treatments |
|
NCT00734123 |
PRIMARIA | P4 |
Unknown status |
Atherosclerosis |
2009-04-01 |
2019-03-18 |
Treatments |